Tratamiento y evolución del síndrome de tormenta de citoquinas asociados a infección por SARS-CoV-2 en pacientes octogenarios

Callejas‐Rubio, José Luis; Millán, Ismael Francisco Aomar; Higueras, Manuela Moreno; Medina, Leopoldo Muñoz; López, María López; Torres, Ángel Ceballos

doi:10.1016/j.regg.2020.05.004

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, 14% present with severe dyspnea and hypoxia and/or pneumonia that affects more than 50% of the lung field in 24–48 h, with a severe course and hospital admission. Multi-organ failure mediated by a cytokine storm is developed by 5%, that requires admission to intensive care units (ICUs) [ 19 ]. Of the cases, 2.3% die from complications arising during the COVID-19 process [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…Notably the clinical data published to date indicate that the most common comorbidity of coronavirus disease 2019 (COVID- 19) is hypertension (31.2%), and this is even higher (58.3%) in severe COVID-19 [10]. As guidelines have assessed, renin-angiotensin system blockers (angiotensin-converting enzyme or ACEI/angiotensin II receptor antagonists such as, ARAII) are recommended in the first step of pharmacological treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis

Quesada-Caballero,

Carmona-García,

Chami-Peña

et al. 2023

Medicina

View full text Add to dashboard Cite

Angiotensin II-converting enzyme inhibitors (ACEIs) and selective angiotensin II receptor antagonists (ARAIIs) are widely used antihypertensive agents. Their use has generated controversy due to their possible influence on the health status of chronic patients infected with COVID-19. The objective of this work is to analyze the influence of COVID-19 on chronic hypertensive patients treated with ACEI and ARAII inhibitors. A systematic review and meta-analysis in the databases Pubmed, Pro-Quest and Scopus were carried out. The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search equation descriptors were obtained from the Medical Subject Headings (MeSH) thesaurus. The search equation was: “Older AND hypertension AND (COVID-19 OR coronavirus) AND primary care” and its equivalent in Spanish. Nineteen articles were obtained, with n = 10,806,159 subjects. Several studies describe the COVID-19 association with ACEI or ARAII treatment in hypertension patients as a protective factor, some as a risk factor, and others without a risk association. In the case of ACEI vs. ARAII, the risk described for the former has an odds ratio (OR) of 0.55, and for ARAII, an OR of 0.59. Some authors talk about mortality associated with COVID-19 and ACEI with a half ratio (HR) of 0.97, and also associated ARAIIs with an HR of 0.98. It is recommended to maintain the use of the renin–angiotensin–aldosterone axis in the context of the COVID-19 disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis

Quesada-Caballero,

Carmona-García,

Chami-Peña

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…En la relación bidireccional DM y COVID-19, la diabetes añade peor pronóstico a la infección, y esta última se ha asociado al comienzo diabético. A este hecho, debemos sumar el papel de los fármacos administrados para el tratamiento de la COVID-19, algunos de ellos, como los glucocorticoides, con claro perfil hiperglicémico 12 . Dado el posible efecto perjudicial de estos fármacos en el paciente diabético con COVID-19 deberían administrarse con la máxima precaución y junto a otros principios activos con efecto antiinflamatorio como el tocilizumab 13 .…”

unclassified